Ignite Creation Date:
2024-05-06 @ 10:50 AM
Last Modification Date:
2024-10-26 @ 12:36 PM
Study NCT ID:
NCT03366571
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2021-04-14
First Post:
2016-07-29
Brief Title:
Improvement of Hard Endpoint in Chronic Hepatitis B Patients Treated With Antiviral Therapy
Sponsor:
Beijing Friendship Hospital
Organization:
Beijing Friendship Hospital
Study Overview
Official Title:
Improvement of Hard Endpoint in Chronic Hepatitis B Patients Treated With Antiviral Therapy
Status:
ACTIVE_NOT_RECRUITING
Status Verified Date:
2021-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Patients who have completed 3 years follow-up of the past Beijing Science and Technology Commission Research will receive another 7-years anti-viral therapy Patients will be assessed at baseline and every six months for blood cell count liver function test HBVDNA AFP prothrombin time liver ultrasonography and Fibroscan CT or MRI and endoscopy will be performed at baseline and 7 years At the end of the study the cumulative rate of clinical hepatic hard endpoint will be calculated
Detailed Description:
Patients who have completed 3 years follow-up of the past Beijing Science and Technology Commission Research will receive another 7-years anti-viral therapy Patients will be assessed at baseline and every six months for blood cell count liver function test HBVDNA AFP prothrombin time liver ultrasonography and Fibroscan CT or MRI and endoscopy will be performed at baseline and 7 years At the end of the study the cumulative rate of clinical hepatic hard endpoint will be calculated
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None